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Abstract
Background and methods: Human metapneumovirus (hMPV) is a recently discovered
respiratory virus associated with bronchiolitis, pneumonia, croup and exacerbations of asthma.
Since respiratory viruses are frequently detected in patients with acute exacerbations of COPD
(AE-COPD) it was our aim to investigate the frequency of hMPV detection in a prospective cohort
of hospitalized patients with AE-COPD compared to patients with stable COPD and to smokers
without by means of quantitative real-time RT-PCR.
Results: We analysed nasal lavage and induced sputum of 130 patients with AE-COPD, 65 patients
with stable COPD and 34 smokers without COPD. HMPV was detected in 3/130 (2.3%) AE-COPD
patients with a mean of 6.5 × 105 viral copies/ml in nasal lavage and 1.88 × 105 viral copies/ml in
induced sputum. It was not found in patients with stable COPD or smokers without COPD.
Conclusion: HMPV is only found in a very small number of patients with AE-COPD. However it
should be considered as a further possible viral trigger of AE-COPD because asymptomatic
carriage is unlikely.
Background
Respiratory viruses play an important role in exacerba-
tions of COPD and this has been increasingly recognised
since the application of molecular detection methods
[1,2]. The most prevalent viruses detected by polymerase
chain reaction so far were respiratory syncytial virus
(RSV), Influenza A, Rhinovirus and Parainfluenza 3.
Human metapneumovirus (hMPV) is a recently discov-
ered respiratory virus first isolated from a dutch child with
lower respiratory tract infection (LRTI)[3]. World wide
distribution is probable since it has been isolated in North
America[4], Brasil[5], Japan[6], Australia[7] and the
United Kingdom[8] from children with LRTI in the win-
ter/spring seasons. Recent publications show a detection
rate of 3.9 to 7% in children hospitalized for LRTI [9-12].
When outpatients are investigated for the presence of
hMPV the detection rates are higher ranging from 6.2[13]
to 12%[14].
HMPV has been recognized as a member of the Paramyxo-
viridae like RSV and it is not only associated with bronchi-
olitis in most cases, but also with pneumonia, croup and
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exacerbations of asthma[14,15], diseases which share
some features with COPD. Up to date reports about hMPV
in adults are scarce. In a general Canadian population
14.8% of patients of all age groups with acute respiratory
tract infections were hMPV positive. Thirty-three percent
of hMPV-infected patients were hospitalized and the hos-
pitalization rates were significantly higher among patients
below 5 years and those over 50 years of age[16]. In
another prospective cohort of adults, hMPV was detected
in 4.5% of all illnesses but also in 4.1% of asymptomatic
subjects. HMPV was most prevalent in young adults with
children and in frail elderly[17]. HMPV infection can be
severe since the virus was isolated from the lungs from a
previously healthy man who died from acute pneumo-
nia[18]. The role of hMPV in acute exacerbations of
COPD (AE-COPD) has been studied recently in outpa-
tients and only low frequencies have been
observed[17,19]. Up to now the prevalence of hMPV in
patients hospitalized with AE-COPD is unknown. Our
aim was therefore to investigate the frequency of detection
of hMPV in a prospective cohort of hospitalized patients
with AE-COPD and to compare these results to patients
with stable COPD and to smokers without COPD.
Subjects, material and methods
Subjects
Three different groups were studied. The first group con-
sisted of hospitalized patients with an acute exacerbation
of COPD (AE-COPD), the second group were subjects
with stable COPD and the third group was composed of
smokers without COPD. The groups were defined as pre-
viously published[20]. Briefly AE-COPD patients suffered
from COPD as defined by GOLD[21]. Acute exacerbation
was characterized by worsening in dyspnea, cough, and
expectoration. A routine posterior-anterior chest radio-
graph was evaluated on admission by expert radiologists
to exclude other other reasons for increased symptoms as
pneumonia, tuberculosis, pulmonary fibrosis, bron-
chiectasis, bronchial carcinoma or congestive heart fail-
ure.Stable COPD patients did not have an exacerbation
within the last 30 days prior to hospital admission and
had no changes in therapy within the last 14 days (includ-
ing inhaled and oral medication) and had been admitted
for other medical reasons into departments of internal
medicine other than pulmonary care. COPD subjects were
recruited in a 2:1 ratio each month in order to prevent sea-
sonal selection bias. Smokers  have been smoking more
than 10 pack-years, could have chronic symptoms like
cough and phlegm but did not report dyspnea and did not
have bronchial obstruction (FEV1/FVC>70%, FEV1>80%
predicted). None of the smokers had a history of COPD or
asthma, nor was using systemic or topic pulmonary med-
ication. The smokers were recruited either from our smok-
ing cessation initiative or by newspaper advertisement.
The study was approved by the ethical committee of the
Ruhr-University of Bochum, Germany. Written informed
consent was obtained from all patients and control sub-
jects before inclusion in the study.
Diagnostic methods
Clinical evaluation, spirometric tests, nasal lavage,
induced sputum, specimen processing and viral ribonu-
cleic acid (RNA) extraction were carried out as described
by Rohde et al[2]. Elution volume was 100 µl. cDNA was
generated with random-hexamer primers as previously
published[2].
Detection of hMPV by real-time Reverse Transcriptase 
PCR
A hMPV-specific real-time RT-PCR designed and evalu-
ated by Maertzdorf et al was used[22]. Primers and probe
are localized within the nucleoprotein gene (NL-N) and
the presence of a degenerate base within the probe allows
detection of all four genetic lineages of hMPV.
The assays were performed using the TaqMan® PCR Core
Kit. The final volume was 25 µl containing 500 nM of the
forward primer (NL-N-forward (5'-CATATAAGCAT-
GCTATATTAAAAGAGTCTC-3')), 250 nM of the reverse
primer (NL-N-reverse (5'-CCTATTTCTGCAGCATATTTG-
TAATCAG-3')) and 500 nM of the probe (NL-N-probe (5'-
FAM-TGYAATGATGAGGGTGTCACTGCGGTTG-TAMRA-
3', in which Y is either a C or a T residue). Nuclease-free
water was used as negative control and a plasmid contain-
ing the N gene of hMPV (kindly provided by James
Simon, VIRONOVATIVE, EUR Holding, Erasmus Univer-
sity Rotterdam) was used as a positive control in all PCR
runs. Cycling parameters were as follows: 5 min at 95°C,
45 cycles of 30 s at 95°C and 1 min at 60°C. Amplifica-
tion and detection of RNA from virus isolates or clinical
specimens were performed using the GeneAmp® 5700
Sequence Detection System (Applied Biosystems). The
real-time PCR product was cloned with the QIAGEN® PCR
cloning kit (QIAGEN, Hilden, Germany) and this stand-
ard plasmid DNA was used for absolute quantification of
hMPV viral load. Calculations were performed as previ-
ously described for absolute quantification of RSV viral
load[23].
Statistical analysis
The primary objective of this study was to compare the fre-
quency of hMPV detection in respiratory specimens
between COPD patients with or without an acute exacer-
bation and smokers without COPD.
Continuous data were checked for normal distribution
using the Kolmogorov-Smirnov test. The data were of
non-parametrical distribution and results were expressed
as median and range. Differences between groups wereRespiratory Research 2005, 6:150 http://respiratory-research.com/content/6/1/150
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assessed by Kruskal-Wallis test. To further analyse signifi-
cant differences between two individual groups a pair wise
comparison by two-sided Mann-Whitney U-test was per-
formed. All significance levels were set to 5%. Data were
analysed and processed using SPSS Version 12.0 on a Win-
dows XP operating system.
Results
Clinical symptoms
A total of 229 subjects were investigated between October
1999 and June 2004: 130 patients with AE-COPD, 65
patients with stable COPD and 34 smokers without
COPD. The clinical characteristics and lung function
measurements are summarized in table 1. FEV1, FEV1 in %
of predicted value and FEV1/FVC were normal in smokers,
significantly decreased in stable COPD patients (all) and
further significantly decreased in AE-COPD patients (all p
< 0.05 compared to stable COPD and all p < 0.001 com-
pared to smokers).
Prevalence of hMPV
HMPV could be detected in three subjects. All these sub-
jects were AE-COPD patients. The prevalence of hMPV in
AE-COPD patients was 2.3%. The virus was simultane-
ously detected in nasal lavage and induced sputum in one
patient only. The viral load was about 100 times higher in
nasal lavage than in induced sputum in this patient. Over-
all the viral load in nasal lavage was about 3.5 times
higher compared to induced sputum (for details see table
2). The hMPV positive patients did not differ significantly
from other AE-COPD patients when clinical parameters
and lung function were analysed. hMPV was detected in
the winter season only.
Discussion
The main finding of this controlled study investigating the
incidence of hMPV in subjects with COPD and smokers
without COPD is that this recently discovered respiratory
virus was detectable only during exacerbation of COPD.
The frequency of detection was very low but in positive
cases the viral load was considerable. There was no detec-
tion in patients with stable COPD or smokers without
COPD.
Our findings are in agreement with other studies in adults.
Recently Vicente et al[19] reported about the incidence of
hMPV in 89 COPD patients. Five patients (5.5%) were
hMPV positive. Two of these patients had to be transferred
to hospital. Although this was not a controlled study and
not all details of the study are available due to the fact that
the data were published in form of a letter, these results
support our findings. The incidence of hMPV in this and
in our study is low compared to other respiratory viruses.
In a similar previous study we found that Picornaviruses
were detectable in 36% of AE-COPD patients, Influenza A
in 25% and Respiratory syncytial virus in 22%[2]. There is
another prospective cohort study of adults in which hMPV
was detected in 4.5% of all illnesses. HMPV was most
prevalent in young adults with children and in frail elderly
from long term care facilities[17]. Unfortunately this
report does not specify how many of the elderly patients
suffered from COPD. In our asymptomatic smokers with-
out COPD hMPV could not be detected. A recent study
investigating nasal secretions from adults with and with-
out respiratory illnesses found hMPV in 5 of 146 ill
patient and in none of 158 control subjects, strongly sup-
porting our data[24]. A further recent study found hMPV
Table 1: Clinical characteristics
AE-COPD Stable COPD Smokers
Age in years 66 [41–80] 66 [45–81] 51 [44–68]
Pack years 32 [2–120] 33 [2–120] 40 [15–92]
FEV1 in l 1.0 [0.4–2.2] 1.3 [0.8–2.8] 3.2 [2.0–5.0]
FEV1 in %predicted 35.2 [18.7–74.1] 44.2 [22.0–93.7] 100.3 [75.6–141.0]
FEV1/FVC in % 46.0 [24.0–69.0] 52.2 [27.0–70.0] 79.8 [72.3–89.6]
AE = Acute exacerbation of COPD
Table 2: Viral loads and month of detection of hMPV
Patient No. VL Nose [copies/ml] VL Sputum [copies/ml] Month of detection
11 . 2 9  ×  1 0 6 1.28 × 104 3/2001
26 . 7 3  ×  1 0 3 -3 / 2 0 0 1
3 - 3.63 × 105 1/2002
Mean VL: [copies/ml] 6.5 × 105 1.88 × 105
VL = viral load, Nose refers to results form nasal lavage, Sputum refers to results from induced sputumRespiratory Research 2005, 6:150 http://respiratory-research.com/content/6/1/150
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in two out of 111 adult patients (1.8%) who presented to
the emergency department for AE-COPD during 2 winter/
spring seasons in Quebec, Canada, also in support of our
findings[25]. In a US American study investigating clinical
samples collected between 1991 and 1995, hMPV could
not be detected at all in 196 patients indicating important
geographical and seasonal differences in hMPV preva-
lence[26]. Taken together the results presented here are in
keeping with other studies in adults and add important
information on the prevalence of hMPV in hospitalized
AE-COPD.
To our knowledge this is the first study analysing the viral
load of hMPV in COPD patients. We found a mean of 6.5
× 105 viral copies/ml in nasal lavage and 1.88 × 105 viral
copies/ml in induced sputum. These values indicate that
hMPV may have been the infectious agent triggering exac-
erbation in these patients. Viral load cut-off values for
infectivity in COPD exacerbations have not been studied
in detail yet and need further investigation. However, viral
loads between 1120 copies/ml in Cytomegalovirus infec-
tion in lung-transplant patients[27] and 5.8log10 copies/
ml in SARS[28] have been considered to indicate infec-
tious disease. Moreover hMPV was only found in acute
exacerbation and not in stable disease or in smokers with-
out COPD supporting a triggering role in AE-COPD.
HMPV infection can be severe since it was isolated from
the lungs from a previously healthy man who died from
acute pneumonia[18]. Our hMPV positive patients did
not differ in their clinical characteristics or lung function
from the other AE-COPD patients which does not indicate
a more severe course of AE-COPD in these patients.
Conclusion
Taken together this is the first controlled study on the rel-
evance of hMPV in hospitalized AE-COPD. HMPV was
detected in a very low frequency but with noticeable viral
load in AE-COPD patients. Given that asymptomatic car-
riage of hMPV is very unlikely it should be considered as
another possible trigger of AE-COPD. Since every AE-
COPD has considerable impact on the course of the dis-
ease and regional outbreaks of hMPV are possible it
should be included into future diagnostic and therapeutic
considerations.
List of abbreviations
AE-COPD = Acute Exacerbations of Chronic Obstructive
Pulmonary Disease
FEV1 = Forced Expiratory Volume in one second
FVC = Functional Vital Capacity
GOLD = Global initiative for chronic Obstructive Lung
Disease
LRTI = Lower Respiratory Tract Infection
hMPV = human Metapneumovirus
NL-N = Nucleoprotein gene of hMPV
RSV = Respiratory Syncytial Virus
RT-PCR = Reverse Transcription Polymerase Chain Reac-
tion
RNA = Ribonucleic Acid
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
GR contributed to the conception and design of the study,
analysis and interpretation of data, performed the statisti-
cal analysis and drafted the manuscript. IB was responsi-
ble for the detection of hMPV by real-time Reverse
Transcriptase PCR, analysis of data and helped to draft the
manuscript, UA and JK were responsible for recruitment,
clinical examination and obtaining the specimens of the
patients and control subjects, RR was also responsible for
the recruitment of subjects and was involved in the detec-
tion of hMPV, TTB participated in the design and coordi-
nation of the study, AB contributed to the design of the
study, the analysis and interpretation of data and revised
the manuscript critically for important intellectual con-
tent, GSW has made contributions to conception and
design of the study, the interpretation of data and revised
the manuscript critically for important intellectual con-
tent. All authors read and approved the final manuscript.
Acknowledgements
The authors are grateful to E. Dretaki-Schnackenberg, B. Schärling and S. 
Werner for their excellent technical assistance (all from the University 
Hospital Bergmannsheil, Dept of Internal Medicine, Division of Pneumol-
ogy, Allergology and Sleep Medicine, Germany). The authors thank James 
Simon (VIRONOVATIVE, EUR Holding, Erasmus University Rotterdam) 
for the kind gift of a plasmid containing the N gene of hMPV.
Supported by Bundesministerium für Bildung und Forschung (BMBF) grant 
#01GC0101 and Scientific Research Committee of the University Hospital 
Bergmannsheil. Torsten Bauer was partially funded by BMBF grants 
#01KI0103-105.
References
1. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G,
Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedz-
icha JA: Respiratory Viruses, Symptoms, and Inflammatory
Markers in Acute Exacerbations and Stable ChronicPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2005, 6:150 http://respiratory-research.com/content/6/1/150
Page 5 of 5
(page number not for citation purposes)
Obstructive Pulmonary Disease.  Am J Respir Crit Care Med 2001,
164:1618-1623.
2. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, Bufe
A, Schultze-Werninghaus G: Respiratory viruses in exacerba-
tions of chronic obstructive pulmonary disease requiring
hospitalization - a case-control study.  Thorax 2003, 58:37-42.
3. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R,
Fouchier RA, Osterhaus AD: A newly discovered human pneu-
movirus isolated from young children with respiratory tract
disease.  Nat Med 2001, 7:719-724.
4. Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS: Human
metapneumovirus infection in the United States: clinical
manifestations associated with a newly emerging respiratory
infection in children.  Pediatrics 2003, 111:1407-1410.
5. Cuevas LE, Nasser AM, Dove W, Gurgel RQ, Greensill J, Hart CA:
Human metapneumovirus and respiratory syncytial virus,
Brazil.  Emerg Infect Dis 2003, 9:1626-1628.
6. Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Hara M, Takahashi
Y, Kobayashi K: Human metapneumovirus infection in Japa-
nese children.  J Clin Microbiol 2004, 42:126-132.
7. Nissen MD, Siebert DJ, Mackay IM, Sloots TP, Withers SJ: Evidence
of human metapneumovirus in Australian children.  Med J Aust
2002, 176:188.
8. Stockton J, Stephenson I, Fleming D, Zambon M: Human metap-
neumovirus as a cause of community-acquired respiratory
illness.  Emerg Infect Dis 2002, 8:897-901.
9. Mullins JA, Erdman DD, Weinberg GA, Edwards K, Hall CB, Walker
FJ, Iwane M, Anderson LJ: Human metapneumovirus infection
among children hospitalized with acute respiratory illness.
Emerg Infect Dis 2004, 10:700-705.
10. Jartti T, Lehtinen P, Vuorinen T, Osterback R, van den HB, Osterhaus
AD, Ruuskanen O: Respiratory picornaviruses and respiratory
syncytial virus as causative agents of acute expiratory
wheezing in children.  Emerg Infect Dis 2004, 10:1095-1101.
11. IJpma FF, Beekhuis D, Cotton MF, Pieper CH, Kimpen JL, van den
Hoogen BG, van Doornum GJ, Osterhaus DM: Human metapneu-
movirus infection in hospital referred South African chil-
dren.  J Med Virol 2004, 73:486-493.
12. van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ,
Beyer WE, de Groot R, Osterhaus AD, Fouchier RA: Prevalence
and clinical symptoms of human metapneumovirus infection
in hospitalized patients.  J Infect Dis 2003, 188:1571-1577.
13. McAdam AJ, Hasenbein ME, Feldman HA, Cole SE, Offermann JT,
Riley AM, Lieu TA: Human metapneumovirus in children
tested at a tertiary-care hospital.  J Infect Dis 2004, 190:20-26.
14. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus
JM, Edwards KM, Wright PF, Crowe JEJ: Human Metapneumovi-
rus and Lower Respiratory Tract Disease in Otherwise
Healthy Infants and Children.  The New England Journal of Medicine
2004, 350:443-450.
15. Laham FR, Israele V, Casellas JM, Garcia AM, Lac Prugent CM, Hoff-
man SJ, Hauer D, Thumar B, Name MI, Pascual A, Taratutto N, Ishida
MT, Balduzzi M, Maccarone M, Jackli S, Passarino R, Gaivironsky RA,
Karron RA, Polack NR, Polack FP: Differential production of
inflammatory cytokines in primary infection with human
metapneumovirus and with other common respiratory
viruses of infancy.  J Infect Dis 2004, 189:2047-2056.
16. Bastien N, Ward D, Van Caeseele P, Brandt K, Lee SH, McNabb G,
Klisko B, Chan E, Li Y: Human metapneumovirus infection in
the Canadian population.  J Clin Microbiol 2003, 41:4642-4646.
17. Falsey AR, Erdman D, Anderson LJ, Walsh EE: Human metapneu-
movirus infections in young and elderly adults.  J Infect Dis
2003, 187:785-790.
18. Chan PK, To KF, Wu A, Tse GM, Chan KF, Lui SF, Sung JJ, Tam JS,
Tomlinson B: Human metapneumovirus-associated atypical
pneumonia and SARS.  Emerg Infect Dis 2004, 10:497-500.
19. Vicente D, Montes M, Cilla G, Perez-Trallero E: Human metapneu-
movirus and chronic obstructive pulmonary disease.  Emerg
Infect Dis 2004, 10:1338-1339.
20. Rohde G, Gevaert P, Holtappels G, Fransen L, Borg I, Wiethege A,
Arinir U, Schultze-Wernighaus G, Bachert C: Soluble IL-5 recep-
tor a is increased in acute exacerbation of COPD.  Int Arch
Allergy Immunol 2004, 135:54-61.
21. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global
strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO Glo-
bal Initiative for Chronic Obstructive Lung Disease (GOLD)
Workshop summary.  Am J Respir Crit Care Med 2001,
163:1256-1276.
22. Maertzdorf J, Wang CK, Brown JB, Quinto JD, Chu M, de Graaf M,
van den Hoogen BG, Spaete R, Osterhaus ADME, Fouchier RAM:
Real-Time Reverse Transcriptase PCR Assay for Detection
of Human Metapneumoviruses from All Known Genetic Lin-
eages.  J Clin Microbiol 2004, 42:981-986.
23. Borg I, Rohde G, Loeseke S, Bittscheid J, Schultze-Werninghaus G,
Stephan V, Bufe A: Evaluation of a quantitative real-time PCR
for the detection of RSV in pulmonary diseases.  Eur Respir J
2003, 21:944-951.
24. Falsey AR, Criddle MC, Walsh EE: Detection of respiratory syn-
cytial virus and human metapneumovirus by reverse tran-
scription polymerase chain reaction in adults with and
without respiratory illness.  Journal of Clinical Virology 2005, [Epub
ahead of print]:.
25. Hamelin ME, Cote S, Laforge J, Lampron N, Bourbeau J, Weiss K,
Gilca R, DeSerres G, Boivin G: Human metapneumovirus infec-
tion in adults with community-acquired pneumonia and
exacerbation of chronic obstructive pulmonary disease.  Clin
Infect Dis 2005, 41:498-502.
26. Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB,
Atmar RL: Respiratory viral infections in patients with
chronic, obstructive pulmonary disease.  J Infect 2005,
50:322-330.
27. Riise GC, Andersson R, Bergstrom T, Lundmark A, Nilsson FN, Olof-
sson S: Quantification of Cytomegalovirus DNA in BAL Fluid
: A Longitudinal Study in Lung Transplant Recipients.  Chest
2000, 118:1653-1660.
28. Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, Wong MM,
Hui WT, Poon LL, Tse DM, Chan KS, Woo PC, Lau SK, Peiris JS, Yuen
KY: Viral loads in clinical specimens and SARS manifesta-
tions.  Emerg Infect Dis 2004, 10:1550-1557.